Industries
Wearable Biosensors and Continuous Monitoring
Wearable biosensors transform biological signals—electrochemical, electrophysiological, and optical—into continuous data streams from the skin surface, enabling researchers to capture real-world physiology outside controlled laboratory settings. Abbott FreeStyle Libre and Dexcom CGM systems pioneered commercial continuous monitoring, while startups such as Biolinq, Epicore Biosystems, and Empatica are extending the sensing palette to sweat metabolites, skin temperature, and electrodermal activity. Scientists and clinical teams procure flexible sensor patches, ASIC-integrated data loggers, secure cloud data pipelines, and ISO-13485-compliant device kits for regulatory-grade clinical studies. The decentralized clinical trial boom and FDA Digital Health Center of Excellence are accelerating wearable adoption for endpoint capture. Research purchasers prioritize sensor accuracy, battery life, wireless protocol compatibility, data privacy compliance, and the availability of open APIs for integration with electronic data capture systems and EHRs.
Details
- Companies
- Abbott (Libre CGM)DexcomBiolinqEpicore BiosystemsMC10EmpaticaCorentium
- Market Size
- $22 billion (2024), projected $68 billion by 2030 at 20.5% CAGR
- Target Researchers
- Physiologists, clinical trialists, sports scientists, digital health researchers, and bioelectronics engineers developing continuous, non-invasive biomarker monitoring platforms.
- Use Cases
- Continuous glucose monitoring in metabolic studiesReal-time sweat biomarker analysis for hydration and electrolytesAmbulatory ECG and heart-rate variability researchSkin-interfaced sensors for cortisol and lactate in sports scienceWearable EEG for sleep and neurofeedback studiesRemote patient monitoring in decentralized clinical trialsEpidermal electronics for wound healing feedback